Expanding Medical Device Contract Manufacturing and Adding Value Across the Value Chain
First written in FY2018-Q2. 19 of 28 entries say "Advanced", first in FY2018-Q3. Latest entry: 2026-09-30.
The whole theme swung hardest in 2024: 1 of 7 companies on the "Worse" side.
5 other companies' latest entry also says "Advanced".
- 2026-09-30AdvancedEarnings
「Revenue and operating profit both increased year on year, driven by firm demand in the medical device CDMO business and resilient demand in the pharmaceutical CDMO business.」
Against a backdrop of demand for medical device CDMO and pharmaceutical CDMO services, revenue and operating profit in the Medical segment increased year on year. - FY2026-H1AdvancedAnnual report
「During the interim consolidated accounting period, sales and operating profit both increased year on year due to firm demand for medical device CDMO services and solid demand for pharmaceutical CDMO services. As a result, consolidated net sales for the interim period amounted to ¥29,034 million, up 8.0% year on year, and segment profit (operating profit) amounted to ¥1,905 million, up 11.1%.」
Against a backdrop of demand for medical device and pharmaceutical CDMO services, Medical Technology sales increased 8.0% and operating profit increased 11.1%. - 2026-05-12AdvancedEarnings
「Demand in the medical device CDMO and pharmaceutical CDMO businesses remained solid, resulting in year-on-year increases in both net sales and operating profit.」
Demand in the medical device CDMO and pharmaceutical CDMO businesses remained firm, increasing net sales and operating profit in the Medical Business. - FY2025-H1AdvancedAnnual report
「During the interim consolidated accounting period, sales and operating profit increased year on year due to firm demand for core medical device CDMO services and the accumulation of contributions from acquisitions. As a result, consolidated net sales for the interim period amounted to ¥23,459 million, up 6.5% year on year, and segment profit (operating profit) amounted to ¥1,267 million, up 23.2%.」
Firm demand for medical device CDMO services and the accumulation of contributions from acquisitions drove increases of 6.5% in Medical Technology sales and 23.2% in operating profit. - FY2024AdvancedAnnual report
「During the fiscal year, sales and operating profit increased year on year due to firm demand for core medical device CDMO services, contributions from acquisitions and the effects of foreign exchange fluctuations.」
In the Medical Technology business, CDMO demand and contributions from acquired companies resulted in sales of ¥45,622 million and segment profit of ¥2,388 million, with sales up 26.7% and profit up 60.0%. - FY2024-H1AdvancedAnnual report
「During the interim consolidated accounting period, sales and operating profit increased year on year due to firm product demand in the core CDMO business, contributions from acquisitions and the effects of foreign exchange fluctuations. As a result, consolidated net sales for the interim period amounted to ¥22,024 million, up 27.2% year on year, and segment profit (operating profit) amounted to ¥1,168 million, up 13.6%.」
In Medical Technology, contributions from acquisitions began to be reflected in results in addition to firm CDMO demand, increasing sales by 27.2% and segment profit by 13.6%. - FY2024-Q1AdvancedAnnual report
「During the cumulative first quarter, sales increased year on year due to firm product demand in the core CDMO business and contributions from acquired companies. However, operating profit decreased year on year due to the recognition of acquisition-related expenses and other factors. As a result, consolidated net sales for the cumulative first quarter amounted to ¥10,069 million, up 18.1% year on year, while segment profit (operating profit) amounted to ¥408 million, down 17.7%.」
In Medical Technology, sales increased 18.1% due to CDMO demand and contributions from acquired companies, while operating profit decreased 17.7% due to acquisition-related expenses. - FY2023AdvancedAnnual report
「During the fiscal year, product demand in the core CDMO business remained firm amid an active market environment, and sales grew year on year. In addition to demand trends, improvements in productivity and efficiency in response to higher costs resulting from inflation and other factors led to an increase in operating profit year on year. As a result, consolidated net sales for the period amounted to ¥36,011 million, up 10.9% year on year, and segment profit (operating profit) amounted to ¥1,493 million, up 204.6%.」
In Medical Technology, firm CDMO demand and improvements in productivity and efficiency were reflected in earnings, resulting in a 10.9% increase in sales and a 204.6% increase in operating profit. - FY2023AdvancedAnnual report
「Through this acquisition of an equity interest, the Company will contribute to innovation in medical devices by acquiring Isometric’s design and development capabilities related to miniaturizing components, as well as micro-molding technologies, including silicone rubber molding and two-color molding.」
The acquisition of an equity interest in Isometric expanded capabilities in the design and development of small, precision components, micro-molding and assembly for medical device CDMO. - FY2023-Q3AdvancedAnnual report
「During the cumulative nine-month consolidated accounting period, product demand in the core CDMO business remained firm amid an active market environment, and sales grew year on year. In response to higher costs resulting from inflation and other factors, the Company worked to improve productivity and efficiency, resulting in an increase in operating profit year on year. As a result, consolidated net sales for the cumulative nine-month period amounted to ¥26,255 million, up 11.8% year on year, and segment profit (operating profit) amounted to ¥1,308 million, up 764.8%.」
In addition to firm CDMO demand, productivity and efficiency improvements progressed, increasing Medical Technology sales by 11.8% and segment profit by 764.8%. - FY2023-Q2AdvancedAnnual report
「During the cumulative six-month consolidated accounting period, product demand in the core CDMO business remained firm amid an active market environment, and sales grew year on year. In response to higher costs driven by inflation, the Company worked to improve productivity and efficiency, resulting in an increase in operating profit year on year. As a result, consolidated net sales for the cumulative six-month period amounted to ¥17,318 million, up 18.5% year on year, and segment profit (operating profit) amounted to ¥1,028 million, or 2,224.9 times the amount in the same period of the previous year.」
In addition to firm CDMO demand, improvements in productivity and efficiency increased Medical Technology sales by 18.5% and segment profit to ¥1,028 million. - FY2023-Q1AdvancedAnnual report
「During the cumulative first quarter, product demand in the core CDMO business remained firm amid an active business environment, and sales grew year on year. In response to higher labor and raw material costs driven by inflation, the Company worked to improve productivity and efficiency, resulting in an increase in operating profit year on year. As a result, consolidated net sales for the cumulative first quarter amounted to ¥8,525 million, up 27.5% year on year, and segment profit (operating profit) amounted to ¥496 million, up 6,627.5%.」
In the Medical Technology business, CDMO demand remained firm, and improvements in productivity and efficiency drove a substantial increase in sales, up 27.5%, and segment profit, to ¥496 million. - FY2022Firm demand, but higher costs reduce profitAnnual report
「During the consolidated fiscal year, product demand in the core CDMO business remained firm amid an active business environment, and sales grew year on year. However, higher raw material and labor costs weighed on profitability. Although profitability improved in the second half, operating profit decreased year on year.」
In Medical Technology, sales increased 34.3% year on year to ¥32,457 million on CDMO demand, while segment profit fell 36.9% to ¥490 million due to higher raw material and labor costs. - FY2022-Q3Firm demand, but higher costs squeeze profitAnnual report
「During the cumulative nine-month consolidated accounting period, product demand remained firm in the core CDMO and business media businesses amid an active business environment, and sales grew year on year. However, surging raw material prices and higher labor costs in the United States weighed on profitability, and operating profit decreased year on year. As a result, consolidated net sales for the cumulative nine-month period amounted to ¥23,481 million, up 32.1% year on year, while segment profit (operating profit) amounted to ¥151 million, down 80.1%.」
In the Medical Technology business, demand and sales in CDMO and business media increased, but segment profit fell 80.1% year on year due to higher raw material prices and labor costs in the United States. - FY2022-Q2Firm demand, but higher costs squeeze profitAnnual report
「During the cumulative six-month consolidated accounting period, product demand remained firm in CDMO, the core business area, but surging raw material prices and higher labor costs in the United States weighed on profitability. As a result, consolidated net sales for the cumulative six-month period amounted to ¥14,610 million, up 26.9% year on year, while segment profit (operating profit) amounted to ¥0 million, down 99.9%.」
Although CDMO demand and sales increased, segment profit fell 99.9% year on year to ¥0 million due to higher raw material prices and labor costs in the United States. - FY2022-Q1Recovery in demand continues, but higher costs weighAnnual report
「During the cumulative first quarter, product demand remained firm as CDMO continued to recover from COVID-19. However, higher raw material prices and transportation costs, along with rising labor costs in the United States, weighed on profitability. As a result, consolidated net sales for the cumulative first quarter amounted to ¥6,685 million, up 23.5% year on year, while segment profit (operating profit) amounted to ¥7 million, down 97.3%.」
Although CDMO demand continued to recover and sales increased, segment profit fell substantially from the same period of the previous year due to higher raw material prices, transportation costs and labor costs in the United States. - FY2021-Q3Recovery in demand continues, but higher costs weighAnnual report
「During the cumulative nine-month consolidated accounting period, product demand continued to recover from the decline caused by COVID-19, and sales grew steadily year on year. However, surging raw material and labor costs in the United States weighed on profitability, and operating profit was largely unchanged year on year. As a result, consolidated net sales for the cumulative nine-month period amounted to ¥17,776 million, up 15.8% year on year, and segment profit (operating profit) amounted to ¥740 million, up 9.2%.」
In Medical Technology, sales increased as demand continued to recover after COVID-19, but higher raw material and labor costs in the United States weighed on profitability. - FY2021-Q2AdvancedAnnual report
「During the cumulative six-month consolidated accounting period, product demand continued to recover in CDMO and business media, which had declined due to the impact of COVID-19. As a result, consolidated net sales for the cumulative six-month period amounted to ¥11,510 million, up 11.9% year on year, while segment profit (operating profit) amounted to ¥475 million, up 32.0%.」
In Medical Technology, demand for CDMO and business media continued to recover following the decline caused by COVID-19, resulting in sales of ¥11,510 million and segment profit of ¥475 million. - FY2021-Q1AdvancedAnnual report
「During the cumulative first quarter, product demand continued to recover in CDMO and business media, which had declined due to the impact of COVID-19. As a result, consolidated net sales for the cumulative first quarter amounted to ¥5,411 million, down 5.1% year on year, while segment profit (operating profit) amounted to ¥272 million, up 26.9%.」
In Medical Technology, demand for CDMO and business media continued to recover. Although sales decreased year on year, segment profit amounted to ¥272 million, up 26.9% year on year. - FY2020Profit increased despite lower demandAnnual report
「During the consolidated fiscal year, demand for proprietary-branded medical electrodes and personal protective equipment, including face shields, increased due to the impact of COVID-19, absorbing the decline in demand for CDMO products used in elective surgery.」
Higher demand for proprietary-branded medical electrodes and personal protective equipment offset the decline in CDMO demand for products used in elective surgery. Although sales decreased, operating profit in Medical Technology increased 7.7% to ¥989 million. - FY2020-Q3Partially offset lower demandAnnual report
「During the cumulative nine-month consolidated accounting period, demand for products such as proprietary-branded medical electrodes and face shields increased due to the impact of COVID-19, partially offsetting the decline in demand for products used in elective surgery in the contract manufacturing business. Demand for business media products, including those for commercial facilities, declined before gradually recovering. As a result, consolidated net sales for the cumulative nine-month period amounted to ¥15,354 million, down 15.7% year on year, and segment profit (operating profit) amounted to ¥678 million, down 14.0%.」
Higher demand for medical electrodes and face shields partially offset the decline in contract manufacturing demand for products used in elective surgery, but sales and operating profit remained below the levels of the same period of the previous year. - FY2020-Q2Demand mix changed amid COVID-19Annual report
「During the cumulative six-month consolidated accounting period, demand for products such as medical electrodes and face shields increased due to the impact of COVID-19, while demand for products used in elective surgery decreased. Demand for business media products, including those for commercial facilities, also decreased. As a result, consolidated net sales for the cumulative six-month period amounted to ¥10,286 million, down 16.3% year on year, and segment profit (operating profit) amounted to ¥360 million, down 46.4%.」
In the contract manufacturing and medical device businesses, higher demand for medical electrodes and face shields coexisted with lower demand for products used in elective surgery, and sales and operating profit fell below the levels of the same period of the previous year. - FY2019-Q3AdvancedAnnual report
「During the cumulative nine-month consolidated accounting period, product demand remained firm, centered on the core contract manufacturing field, but one-time expenses related to the growth strategy, including acquisitions, were incurred. As a result, consolidated net sales for the cumulative nine-month period amounted to ¥18,207 million, up 13.7% year on year, EBITDA amounted to ¥1,742 million, up 30.7%, and segment profit (operating profit) amounted to ¥265 million, compared with a segment loss (operating loss) of ¥6 million in the same period of the previous year.」
Firm demand for contract manufacturing and the continuing effects of integrating acquired companies resulted in sales of ¥18,207 million and operating profit of ¥265 million in the Medical Technology business, which returned to profitability from an operating loss in the same period of the previous year. - FY2019-Q2AdvancedAnnual report
「During the cumulative six-month consolidated accounting period, product demand remained firm, centered on the core contract manufacturing field. As a result, consolidated net sales for the cumulative six-month period amounted to ¥12,285 million, up 23.0% year on year, EBITDA amounted to ¥1,263 million, up 56.7%, and segment profit (operating profit) amounted to ¥272 million, compared with a segment loss (operating loss) of ¥24 million in the same period of the previous year.」
Demand in the contract manufacturing field remained firm, and the Medical Technology business swung from a loss in the same period of the previous year to segment profit of ¥272 million. - FY2019-Q1AdvancedAnnual report
「During the cumulative first quarter, product demand remained firm, centered on the core contract manufacturing field. As a result, consolidated net sales for the cumulative first quarter amounted to ¥6,145 million, up 25.9% year on year, EBITDA amounted to ¥724 million, up 57.2%, and segment profit (operating profit) amounted to ¥220 million, up 427.2%.」
Firm demand for contract manufacturing of medical devices resulted in sales of ¥6,145 million, EBITDA of ¥724 million and segment profit of ¥220 million in the Medical Technology business. - FY2018AdvancedAnnual report
「During the consolidated fiscal year, product demand remained firm, centered on the core contract manufacturing field, and sales of the proprietary-branded new product, the electrocardiogram electrode “Vermed ClaraView,” progressed smoothly. In addition, the business scale expanded as the results of the 3 companies acquired during the consolidated fiscal year were consolidated.」
Demand for contract manufacturing, the new proprietary-branded product and the consolidation of 3 acquired companies contributed to the expansion of medical device products, sales channels and production capacity, which was reflected in full-year results. - FY2018-Q3AdvancedAnnual report
「During the cumulative nine-month consolidated accounting period, product demand remained firm, centered on the core contract manufacturing field, and the business scale expanded as the results of the acquired companies were consolidated. As a result, consolidated net sales for the cumulative nine-month period amounted to ¥16,015 million, up 22.2% year on year, EBITDA amounted to ¥1,333 million, up 98.6%, and segment loss (operating loss) amounted to ¥11 million, compared with a segment loss (operating loss) of ¥528 million in the same period of the previous year.」
Demand in the contract manufacturing field remained firm, and the consolidation of the acquired companies expanded the business scale. The contribution to results progressed, with sales of ¥16,015 million, EBITDA of ¥1,333 million and segment loss narrowed to ¥11 million. - FY2018-Q2First statedAnnual report
「The Medical Technology Division has made expanding its contract manufacturing business one of its key strategies, as major medical device manufacturers are increasingly focusing on research and development and marketing activities while outsourcing their production processes. Through this acquisition, the Medical Technology Division aims to expand its performance by increasing the added value of the value chain from development and production through sales, by gaining new sales channels for contract manufacturing, expanding production capacity, and enhancing its product development and design capabilities.」
Against the backdrop of major medical device manufacturers increasingly outsourcing their production processes, the Company has identified expansion of the contract manufacturing business as a key strategy and, for the first time, explicitly stated its policy of expanding sales channels, production capacity, and product development and design capabilities through acquisitions to increase value added across the value chain.